Clinical Trial Update: Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating whether melatonin mitigates metabolic adverse effects in patients treated with second generation antipsychotics has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Melatonin (melatonin)

Snippet

Sponsor: Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente | Conditions: Second Generation Antipsychotic Induced Metabolic Adverse Effects | Phase 4 | Status: COMPLETED